MindMaze Therapeutics Holding SA (RLFTY)
OTCMKTS · Delayed Price · Currency is USD
1.410
-0.060 (-4.08%)
At close: Jan 26, 2026
RLFTY Income Statement
Financials in millions CHF. Fiscal year is January - December.
Millions CHF. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 4.05 | 8.42 | 6.03 | 6.08 | 3.32 | - |
| 4.05 | 8.42 | 6.03 | 6.08 | 3.32 | - | |
Revenue Growth (YoY) | -52.81% | 39.52% | -0.79% | 83.11% | - | - |
Cost of Revenue | 1.61 | 2.58 | 1.92 | 1.25 | 0.75 | - |
Gross Profit | 2.44 | 5.84 | 4.11 | 4.83 | 2.57 | - |
Selling, General & Admin | 7.91 | 9.83 | 19.43 | 24.05 | 15.14 | 5.47 |
Research & Development | 1.2 | 1.36 | 1.33 | 12.39 | 19.02 | 13.67 |
Other Operating Expenses | -0.38 | -0.29 | -0.11 | -0.51 | 0.61 | 0.23 |
Operating Expenses | 10.61 | 13.46 | 23.97 | 39.79 | 36.81 | 19.36 |
Operating Income | -8.17 | -7.62 | -19.85 | -34.96 | -34.24 | -19.36 |
Interest Expense | -0.04 | -0.04 | -0.03 | -0.13 | -0.19 | -0.1 |
Interest & Investment Income | 0.09 | 0.19 | 0.09 | 0.02 | 0.04 | 0.01 |
Currency Exchange Gain (Loss) | -0.2 | -0.09 | -0.07 | -0.37 | 0.06 | -0.4 |
Other Non Operating Income (Expenses) | 0.19 | -0.06 | -0.84 | -1.79 | -1.1 | -0.05 |
EBT Excluding Unusual Items | -8.12 | -7.62 | -20.7 | -37.24 | -35.43 | -19.9 |
Merger & Restructuring Charges | - | - | - | - | -1.1 | - |
Impairment of Goodwill | - | - | -6.02 | -1.64 | - | - |
Gain (Loss) on Sale of Investments | - | - | - | 0.45 | -0.05 | -1.2 |
Gain (Loss) on Sale of Assets | 0.9 | 0.9 | 0.13 | - | - | 3.38 |
Asset Writedown | -16.83 | -16.83 | -89.88 | -24.78 | - | 11.2 |
Other Unusual Items | 4.19 | 4.19 | 4.78 | 8.89 | 1.06 | 0.25 |
Pretax Income | -19.86 | -19.36 | -111.68 | -54.32 | -35.53 | -6.26 |
Income Tax Expense | -2.82 | -2.24 | -13.5 | -3.53 | -0.82 | 1.57 |
Net Income | -17.04 | -17.12 | -98.18 | -50.79 | -34.71 | -7.83 |
Net Income to Common | -17.04 | -17.12 | -98.18 | -50.79 | -34.71 | -7.83 |
Shares Outstanding (Basic) | 13 | 13 | 12 | 11 | 9 | 6 |
Shares Outstanding (Diluted) | 13 | 13 | 12 | 11 | 9 | 6 |
Shares Change (YoY) | 0.52% | 6.71% | 11.18% | 17.67% | 48.89% | 14.70% |
EPS (Basic) | -1.36 | -1.37 | -8.35 | -4.80 | -3.86 | -1.30 |
EPS (Diluted) | -1.36 | -1.37 | -8.35 | -4.80 | -3.86 | -1.30 |
Free Cash Flow | -3.54 | -2.93 | -18.06 | -24.16 | -35.72 | -18.25 |
Free Cash Flow Per Share | -0.28 | -0.23 | -1.54 | -2.29 | -3.98 | -3.03 |
Gross Margin | 60.24% | 69.41% | 68.17% | 79.44% | 77.42% | - |
Operating Margin | -201.48% | -90.52% | -329.07% | -574.92% | -1030.89% | - |
Profit Margin | -420.33% | -203.39% | -1627.40% | -835.22% | -1045.02% | - |
Free Cash Flow Margin | -87.22% | -34.81% | -299.32% | -397.29% | -1075.52% | - |
EBITDA | -6.79 | -5.58 | -17.07 | -31.49 | -32.38 | -19.36 |
EBITDA Margin | -167.44% | -66.27% | -282.98% | - | - | - |
D&A For EBITDA | 1.38 | 2.04 | 2.78 | 3.47 | 1.86 | 0 |
EBIT | -8.17 | -7.62 | -19.85 | -34.96 | -34.24 | -19.36 |
EBIT Margin | -201.48% | -90.52% | - | - | - | - |
Revenue as Reported | 5.69 | 9.83 | 6.33 | 7.11 | 4.49 | 0.27 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.